Compendium of Cancer Genome Aberrations

BRST5:Volunteer Assignments and Opportunities: Difference between revisions

VisualWikitext
Created page with "Welcome! For assignments, please see the "Author" column below (highlighted blue). If empty (no name is present), please volunteer to create content for that disease! To vo..."
 
No edit summary
 
(70 intermediate revisions by 4 users not shown)
Line 6: Line 6:


To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
__TOC__
==WHO Classification of Tumours of the Breast (5th Edition) Content==
<br />
{| class="wikitable"
{| class="wikitable" style="margin:auto"
|+<big>WHO Classification of Tumours of the Breast (5th Edition) Content</big>
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
Line 17: Line 18:
!'''Date of Last Editor Review'''
!'''Date of Last Editor Review'''
!'''Notes'''
!'''Notes'''
|- |Usual ductal hyperplasia||Disease||
|-
|Usual Ductal Hyperplasia
|
|Disease
====CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)====
|
----
|
----
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|Disease
|
|
|
|
|
Line 35: Line 51:
|
|
|-
|-
|Atypical Ductal Hyperplasia||Disease||
|[[BRST5:Columnar cell lesions, including flat epithelial atypia|Columnar cell lesions, including flat epithelial atypia]]||Disease||
|
|
|
|
Line 44: Line 60:
|
|
|-
|-
|Sclerosing Adenosis||Disease||
|[[BRST5:Atypical ductal hyperplasia|Atypical ductal hyperplasia]]||Disease||
|
|
|
|
Line 53: Line 69:
|
|
|-
|-
|Apocrine Adenosis and Adenoma||Disease||
|[[BRST5:Sclerosing adenosis|Sclerosing adenosis]]||Disease||
|
|
|
|
Line 62: Line 78:
|
|
|-
|-
|Microglandular Adenosis||Disease||
|[[BRST5:Apocrine adenosis and adenoma|Apocrine adenosis and adenoma]]||Disease||
|
|
|
|
Line 71: Line 87:
|
|
|-
|-
|Radial Scar/Complex Sclerosing Lesion||Disease||
|[[BRST5:Microglandular adenosis|Microglandular adenosis]]||Disease||
|
|
|
|
Line 80: Line 96:
|
|
|-
|-
|Tubular Adenoma||Disease||
|[[BRST5:Radial scar / complex sclerosing lesion|Radial scar/complex sclerosing lesion]]||Disease||
|
|
|
|
Line 89: Line 105:
|
|
|-
|-
|Lactating Adenoma||Disease||
|[[BRST5:Tubular adenoma|Tubular adenoma]]||Disease||
|
|
|
|
Line 98: Line 114:
|
|
|-
|-
|Ductal Adenoma||Disease||
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||
|
|
|
|
Line 107: Line 123:
|
|
|-
|-
|Pleomorphic Adenoma||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Ductal adenoma|Ductal adenoma]]||Disease||
|
|
|
|
Line 116: Line 143:
|
|
|-
|-
|Adenomyoepithelioma||Disease||
|[[BRST5:Pleomorphic adenoma|Pleomorphic adenoma]]||Disease||
|
|
|
|
Line 125: Line 152:
|
|
|-
|-
|Malignant Adenomyoepithelioma||Disease||
|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]||Disease||
|
|
|
|
Line 134: Line 161:
|
|
|-
|-
|Intraductal Papilloma||Disease||
|[[BRST5:Malignant adenomyoepithelioma|Malignant adenomyoepithelioma]]||Disease||
|
|
|
|
Line 143: Line 170:
|
|
|-
|-
|Papillary Ductal Carcinoma In Situ||Disease||
|[[BRST5:Intraductal papilloma|Intraductal papilloma]]||Disease||
|
|
|
|
Line 152: Line 179:
|
|
|-
|-
|Encapsulated Papillary Carcinoma||Disease||
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||
|
|
|
|
Line 161: Line 188:
|
|
|-
|-
|Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
|[[BRST5:Encapsulated papillary carcinoma|Encapsulated papillary carcinoma]]||Disease||
|
|
|
|
Line 170: Line 197:
|
|
|-
|-
|Invasive Papillary Carcinoma||Disease||
|[[BRST5:Solid papillary carcinoma (in situ and invasive)|Solid papillary carcinoma (in situ and invasive)]]||Disease||
|
|
|
|
Line 179: Line 206:
|
|
|-
|-
|Atypical Lobular Hyperplasia||Disease||
|[[BRST5:Invasive papillary carcinoma|Invasive papillary carcinoma]]||Disease||
|
|
|
|
Line 188: Line 215:
|
|
|-
|-
|Lobular Carcinoma In Situ||Disease||
|[[BRST5:Atypical lobular hyperplasia|Atypical lobular hyperplasia]]||Disease||
|
|
|
|
Line 197: Line 224:
|
|
|-
|-
|Ductal Carcinoma In Situ||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||
|
|
|
|
Line 206: Line 244:
|
|
|-
|-
|Invasive Breast Carcinoma of No Special Type||Disease||
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||
|
|
|
|
Line 215: Line 253:
|
|
|-
|-
|Microinvasive Carcinoma||Disease||
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||
|
|
|
|
|
|
|
|
|
|
|-
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||Hieu Nguyen
|9/23/2025
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|Invasive lobular Carcinoma||Disease||
|[[BRST5:Invasive lobular carcinoma|Invasive lobular carcinoma]]||Disease||
|
|
|
|
Line 233: Line 280:
|
|
|-
|-
|Tubular Carcinoma||Disease||
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||
|
|
|
|
Line 242: Line 289:
|
|
|-
|-
|Cribriform Carcinoma||Disease||
|[[BRST5:Cribriform carcinoma|Cribriform carcinoma]]||Disease||
|
|
|
|
Line 251: Line 298:
|
|
|-
|-
|Mucinous Carcinoma||Disease||
|[[BRST5:Mucinous carcinoma|Mucinous carcinoma]]||Disease||
|
|
|
|
Line 260: Line 307:
|
|
|-
|-
|Mucinous Cystadenocarcinoma||Disease||
|[[BRST5:Mucinous cystadenocarcinoma|Mucinous cystadenocarcinoma]]||Disease||
|
|
|
|
Line 269: Line 316:
|
|
|-
|-
|Invasive Micropapillary Carcinoma||Disease||
|[[BRST5:Invasive micropapillary carcinoma|Invasive micropapillary carcinoma]]||Disease||
|
|
|
|
Line 278: Line 325:
|
|
|-
|-
|Carcinoma with Apocrine Differentiation||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Carcinoma with apocrine differentiation|Carcinoma with apocrine differentiation]]||Disease||
|
|
|
|
Line 287: Line 345:
|
|
|-
|-
|Metaplastic Carcinoma||Disease||
|[[BRST5:Metaplastic carcinoma|Metaplastic carcinoma]]||Disease||
|
|
|
|
Line 296: Line 354:
|
|
|-
|-
|Acinic Cell Carcinoma||Disease||
|[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||
|
|
|
|
Line 305: Line 363:
|
|
|-
|-
|Adenoid Cystic Carcinoma||Disease||Katherine Geiersbach / Jun Liao
|[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach;
Jun Liao
|10/12/02022
|10/12/02022
|11/11/2023
|11/11/2023
|COMPLETE
|COMPLETE
|
|
|Hui Chen / Katherine Geiersbach
|Katherine Geiersbach
|12/6/2023
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Secretory Carcinoma||Disease||Hui Chen / Morteza Seifi
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen;
Katherine Geiersbach
|10/12/2022
|10/12/2022
|11/11/2023
|11/11/2023
|PENDING
|COMPLETE
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Mucoepidermoid Carcinoma||Disease||
|[[BRST5:Mucoepidermoid carcinoma|Mucoepidermoid carcinoma]]||Disease||
|
|
|
|
Line 332: Line 392:
|
|
|-
|-
|Polymorphous Adenocarcinoma||Disease||
|[[BRST5:Polymorphous adenocarcinoma|Polymorphous adenocarcinoma]]||Disease||
|
|
|
|
Line 341: Line 401:
|
|
|-
|-
|Tall Cell Carcinoma with Reversed Polarity||Disease||H. Evin Gulbahce
|[[BRST5:Tall cell carcinoma with reversed polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce
|8/11/2023
|8/11/2023
|10/11/2023
|10/11/2023
Line 347: Line 407:
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Neuroendocrine Tumour||Disease||
|[[BRST5:Neuroendocrine tumour|Neuroendocrine tumour]]||Disease||
|
|
|
|
Line 359: Line 419:
|
|
|-
|-
|Neuroendocrine Carcinoma||Disease||
|[[BRST5:Neuroendocrine carcinoma|Neuroendocrine carcinoma]]||Disease||
|
|
|
|
Line 368: Line 428:
|
|
|-
|-
|Hamartoma||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|
====CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|Fibroadenoma||Disease||H. Evin Gulbahce / Patricija Zot
|[[BRST5:Hamartoma|Hamartoma]]||Disease||
|8/11/2023
|
|11/11/2023
|PENDING
|
|
|
|
|
|
|2021 template added
|-
|Phyllodes Tumour||Disease||H. Evin Gulbahce / Patricija Zot / Emilie Lalonde / Katherine Geiersbach
|8/11/2023
|11/11/2023
|PENDING
|
|
|
|
|
|
|2021 template added
|-
|-
|Syringomatous Tumour||Disease||
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| ||
|
|
|
|
Line 404: Line 478:
|
|
|-
|-
|Nipple Adenoma||Disease||
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde;
|
H. Evin Gulbahce;
|
 
Katherine Geiersbach
|8/11/2023
|11/11/2023
|COMPLETE
|
|
|
|
|1/8/2025
|2024 template added
|-
|
|
====CHAPTER 4 (TUMOURS OF THE NIPPLE)====
|
|
----
|
|
|-
----
|Paget disease of the Breast||Disease||
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|Haemangioma||Disease||
|[[BRST5:Syringomatous tumour|Syringomatous tumour]]||Disease||
|
|
|
|
Line 431: Line 520:
|
|
|-
|-
|Angiomatosis||Disease||
|[[BRST5:Nipple adenoma|Nipple adenoma]]||Disease||
|
|
|
|
Line 440: Line 529:
|
|
|-
|-
|Atypical Vascular Lesions||Disease||
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||
|
|
|
|
Line 449: Line 538:
|
|
|-
|-
|Postradiation Angiosarcoma of the Breast||Disease||
|
|
====CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)====
|
----
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|Primary Angiosarcoma of the Breast||Disease||
|[[BRST5:Haemangioma|Haemangioma]]||Disease||
|
|
|
|
Line 467: Line 568:
|
|
|-
|-
|Nodular Fasciitis||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Angiomatosis|Angiomatosis]]||Disease||
|
|
|
|
Line 476: Line 588:
|
|
|-
|-
|Myofibroblastoma||Disease||
|[[BRST5:Atypical vascular lesions|Atypical vascular lesions]]||Disease||
|
|
|
|
Line 485: Line 597:
|
|
|-
|-
|Desmoid Fibromatosis||Disease||
|[[BRST5:Postradiation angiosarcoma of the breast|Postradiation angiosarcoma of the breast]]||Disease||
|
|
|
|
|
Line 493: Line 604:
|
|
|
|
|-
|Inflammatory Myofibroblastic Tumour||Disease||Yajuan Liu
|8/11/2023
|11/11/2023
|COMPLETE
|
|
|Katherine Geiersbach
|12/6/2023
|2021 template added
|-
|-
|Schwannoma||Disease||
|[[BRST5:Primary angiosarcoma of the breast|Primary angiosarcoma of the breast]]||Disease||
|
|
|
|
Line 512: Line 615:
|
|
|-
|-
|Neurofibroma||Disease||
|[[BRST5:Nodular fasciitis|Nodular fasciitis]]||Disease||
|
|
|
|
Line 521: Line 624:
|
|
|-
|-
|Granular Cell Tumour||Disease||
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]||Disease||
|
|
|
|
Line 530: Line 633:
|
|
|-
|-
|Leiomyoma||Disease||
|[[BRST5:Desmoid fibromatosis|Desmoid fibromatosis]]||Disease||
|
|
|
|
|
Line 537: Line 641:
|
|
|
|
|-
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Katherine Geiersbach
|8/11/2023
|11/11/2023
|COMPLETE
|
|
|Katherine Geiersbach
|1/8/2025
|2024 template
|-
|-
|Leiomyosarcoma||Disease||
|[[BRST5:Schwannoma|Schwannoma]]||Disease||
|
|
|
|
Line 548: Line 660:
|
|
|-
|-
|Lipoma||Disease||
|[[BRST5:Neurofibroma|Neurofibroma]]||Disease||
|
|
|
|
Line 557: Line 669:
|
|
|-
|-
|Angiolipoma||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Granular cell tumour|Granular cell tumour]]||Disease||
|
|
|
|
Line 566: Line 689:
|
|
|-
|-
|Liposarcoma||Disease||
|[[BRST5:Leiomyoma|Leiomyoma]]||Disease||
|
|
|
|
Line 575: Line 698:
|
|
|-
|-
|Pseudoangiomatous Stromal Hyperplasia||Disease||
|[[BRST5:Leiomyosarcoma|Leiomyosarcoma]]||Disease||
|
|
|
|
Line 584: Line 707:
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
|[[BRST5:Lipoma|Lipoma]]||Disease||
|
|
|
|
Line 593: Line 716:
|
|
|-
|-
|Follicular Lymphoma||Disease||
|[[BRST5:Angiolipoma|Angiolipoma]]||Disease||
|
|
|
|
Line 602: Line 725:
|
|
|-
|-
|Diffuse Large B-cell Lymphoma||Disease||
|[[BRST5:Liposarcoma|Liposarcoma]]||Disease||
|
|
|
|
Line 611: Line 734:
|
|
|-
|-
|Burkitt Lymphoma||Disease||
|[[BRST5:Pseudoangiomatous stromal hyperplasia|Pseudoangiomatous stromal hyperplasia]]||Disease||
|
|
|
|
Line 620: Line 743:
|
|
|-
|-
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
|
|
====CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)====
|
----
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|Gynaecomastia||Disease||
|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|
|
|
Line 638: Line 773:
|
|
|-
|-
|Carcinoma In Situ||Disease||
|[[BRST5:Follicular lymphoma|Follicular lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|
|
|
Line 647: Line 782:
|
|
|-
|-
|Invasive Carcinoma||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|
|
|
Line 656: Line 802:
|
|
|-
|-
|Metastases to the Breast||Disease||
|[[BRST5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|
|
|
Line 665: Line 811:
|
|
|-
|-
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin / Katherine Geiersbach
|[[BRST5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||
|12/6/2023
|
|3/6/2024
|
|
|
|
|
Line 674: Line 820:
|
|
|-
|-
|Cowden Syndrome||Disease||
|
|
|
====CHAPTER 7 (TUMOURS OF THE MALE BREAST)====
|
|
----
|
|
----
|
|
----
|
|
----
|
|
|-
----
|Ataxia-Telangiectasia||Disease||Evin Gulbahce / Katherine Geiersbach
|12/11/2023
|3/11/2024
|
|
----
|
|
|Katherine Geiersbach
----
|
|
----
|
|
----
|-
|-
|Li-Fraumeni Syndrome, TP53-Associated||Disease||
|[[BRST5:Gynaecomastia|Gynaecomastia]]||Disease||
|
|
|
|
Line 701: Line 850:
|
|
|-
|-
|Li-Fraumeni Syndrome, CHEK2-Associated||Disease||
|[[BRST5:Carcinoma in situ|Carcinoma in situ]]||Disease||
|
|
|
|
Line 710: Line 859:
|
|
|-
|-
|CDH1-Associated Breast Cancer||Disease||
|[[BRST5:Invasive carcinoma|Invasive carcinoma]]||Disease||
|
|
|
|
Line 719: Line 868:
|
|
|-
|-
|PALB2-Associated Cancers||Disease||Constance Albarracin / Katherine Geiersbach
|[[BRST5:Metastases to the breast|Metastases to the breast]]||Disease||
|12/8/2023
|3/8/2024
|
|
|
|
Line 727: Line 874:
|
|
|
|
|-
|Peutz-Jeghers Syndrome||Disease||
|
|
|
|
|-
|
|
====CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)====
|
|
----
|
|
----
|
|
----
|
|
|-
----
|Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
|
|
----
|
|
----
|
|
----
|
|
----
|
|
|
----
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|-
|[[BRST5:BRCA1/2-associated hereditary breast and ovarian cancer syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship statu]]<nowiki/>s [see [[GTS5:PTEN hamartoma tumour syndrome (PTEN)|PTEN hamartoma tumour syndrome (PTEN)]]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|-
|Polygenic Component of Breast Cancer Susceptibility
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
|Disease
|Disease
|Xiaolin Hu
|6/4/2024
|
|
|
|
Line 753: Line 999:
|
|
|
|
|
|Template added (6/4/24)
|
|
|-
|-
|}<br />
|}<br />
Retrieved from "https://test.ccga.io/index.php/BRST5:Volunteer_Assignments_and_Opportunities"